In today’s Pharmaceutical Executive Daily, learn how Abbott is acquiring Exact Sciences in a major diagnostics deal, Novartis is building a new manufacturing hub in North Carolina, and the FDA is rolling out a wide batch of drug approvals.
Welcome to Pharmaceutical Executive Daily, your quick briefing on the top news shaping the pharmaceutical and life sciences industry.
In today’s Pharmaceutical Executive Daily, learn how Abbott is acquiring Exact Sciences in a major diagnostics deal, Novartis is building a new manufacturing hub in North Carolina, and the FDA is rolling out a wide batch of drug approvals.
Abbott Laboratories has agreed to acquire Exact Sciences for approximately $21 billion, giving it a significant entry into the cancer-screening diagnostics market. The move represents a strategic expansion for Abbott beyond its traditional diagnostics and medical devices footprint.
Novartis announced plans to build a flagship manufacturing hub in North Carolina as part of a broader U.S. investment plan. The hub will include new facilities in Durham and Morrisville and is part of a $23 billion investment in U.S. infrastructure over the next five years. The project is expected to strengthen the U.S. supply chain for Novartis’s key medicines and create hundreds of jobs locally.
The FDA has published a long list of new drug approvals, spanning multiple therapeutic areas including oncology and rare disease. This wave of approvals marks continued momentum in innovation and regulatory throughput as the year wraps up.
Thanks for listening to Pharmaceutical Executive Daily. For more updates and in-depth analysis, visit PharmExec.com.
